Introduction
The first causal mutation for Parkinson's disease (PD) was identified in 1997, in the gene SNCA/PARK1. Two other genes [Leucine-rich repeat kinase 2 (LRRK2)/PARK8 and vacuolar protein sorting 35 ortholog (VPS35)] were since conclusively associated with autosomal dominant (AD) and four [parkin/PARK2, PTEN-induced kinase 1 (PINK1)/PARK6, DJ-1/PARK7, ATP13A2/PARK9] with early-onset autosomal recessive (AR) PD (Corti et al., 2011; Vilariño-Güell et al., 2011; Zimprich et al., 2011) . Recently, mutations in eukaryotic translation initiation factor 4-gamma (EIF4G1)/PARK18 was reported as a probable cause of AD late-onset PD (Chartier-Harlin et al., 2011) . Here, to 4/Lesage/NBA-12-215 4 determine the frequency and pathogenicity of EIF4G1 variants, we screened all 31 EIF4G1 coding exons in a series of AD PD patients and matched controls.
Methods

Subjects
We selected 251 index cases (>90% French) with dominant inheritance [≥2 affected individuals in 2 successive generations identified by examination of secondary cases (n=101) or family history (n=150)]. Most (>73%) had definite PD (Hughes et al., 1992) : mean age at onset in 140 male and 111 female index patients was 50.2±12.0 years (range 14-86); age at examination, 58.2±11.8 years (range 24-87). Control subjects, 236 Europeans (134 males, 102 females, mainly spouses) without family histories of PD, were examined at age 58.1±11.8 (range 31-85). Patients with SNCA multiplications, SCA2 CAG repeat expansions and VPS35 mutations were excluded. Since digenic parkinsonism has been observed (Dächsel et al., 2006) , subjects were screened for LRRK2 p.G2019S (most already reported, Lesage et al., 2009 ).
Molecular methods
The local ethics committee approved the study. Peripheral blood was collected, with written informed consent, and DNA extracted from leukocytes by standard procedures. The 31 EIF4G1 coding exons and exon-intron junctions were sequenced as reported, with modifications (Chartier-Harlin et al., 2011) . Variant frequencies were compared in patients and controls with the chi-square test (significant at p<0.05). Mutation nomenclature follows HGVS recommendations: +1 is A of ATG initiation codon in NCBI Reference Sequences 
Results
Sixty sequence variants (35 intronic, 25 exonic) were found (Tables 1, 2). Twelve coding variants, including six novel, were synonymous (five only detected in controls). We also identified four novel, rare non-synonymous amino acid substitutions or in-frame insertions/deletions (indels) (p.A433V/c.1298C>T, p.E465del/c.1384_1386delGAA, p.E462delInsGK/c.1384_1386insGAA, p.P446H/1337C>A) ( Table 1) ; none affected protein function in silico. Segregation analysis was not possible except for p.E462delInsGK, found in two affected siblings. Of the 12 rare missense or indels variants, six were present exclusively in cases and three in controls, including two reportedly putative disease-causing mutations (Table 1) .
Male patient FPD-832-1 carried LRRK2 p.G2019S in addition to EIF4G1 p.G686C.
Diagnosed at age 58, his Hoehn and Yahr score, at age 68, was 2/5; his UPDRS III motor score, 41/132 "off" and 24 "on," reflected a good L-dopa response; he had no cognitive impairment [Mini Mental State Examination (MMSE) =28/30]. Female patient FPD-252-13, with EIF4G1 p.G686C, had PD according to UK Brain Bank criteria (Hughes et al., 1992) , onset at age 52, a Hoehn and Yahr score of 2/5, at age 67, excellent L-dopa response, peakdose dyskinesias, but no cognitive impairment (MMSE=29/30).
Variants with minor allele frequencies (MAF) ≥0.05 (n=9) were tested for Hardy-Weinberg equilibrium (HWE) and association with PD in patients and controls ( Table 2) .
Two of them (rs939317 and rs1879244) deviated from equilibrium in the patient group with p-values of 0.01 and 0.02, respectively versus 0.31and 0.35 in the healthy control group. None of the polymorphic variants showed an association with PD in the case-control study, except for the rs9846954 variant (genotype, p=0.03; alleles, p=0.007; Table 2 ) that was not significant after Bonferroni correction. 6/Lesage/NBA-12-215 6
Discussion
Linkage and candidate gene analysis identified the p.R1205H mutation in EIF4G1, encoding a component of the eIF4F translation initiation complex that regulates cell survival in response to stressors, in a large French family with AD late-onset PD and seven smaller families of various origins, probably resulting from an ancestral founder (Chartier-Harlin et al., 2011) . Screening additional patients with parkinsonism and Lewy body disease identified four less frequent putatively disease-causing mutations, p.A502V, p.G686C, p.S1164R and p.R1197W, absent from ~4,000 controls, but their involvement in disease pathogenesis remains inconclusive, in absence of segregation analyses. The most frequently reported EIF4G1 mutation, p.R1205H, was not present in the 487 individuals tested here, nor p.A502V, but the rare p.G686C variant was found in two PD families, one with LRRK2 p.G2019S, suggesting that EIF4G1 mutations are not a common cause of PD at least in our population; the p.R1197W variant however found in a control is probably a rare benign polymorphism. In our study, we identified three novel rare missense and indels variations, present only in cases but their pathogenicity remains to be proven in the absence of segregation data and deleterious effects predicted in silico. This result highlights the difficulties of interpreting the occurrence of rare missense variations in an isolated sporadic patient or in families that are too small to be informative in segregation analyses, even if they are not found in a large number of controls.
As previously reported (Chartier-Harlin et al., 2011) , no significant association with PD was found. Our cases with p.G686C mutations had idiopathic PD, good responses to L-DOPA and no dementia, consistent with the late-onset idiopathic Lewy body parkinsonism previously reported in EIF4G1 patient carriers.
In conclusion, we do not provide conclusive evidence that the variants identified are deleterious. In Chartier-Harlin and colleagues' study and in ours, EIF4G1 variants seem to be 7/Lesage/NBA-12-215 7 very rare in the PD population. Large multi-center studies, as performed for the LRRK2 gene are needed to determine the frequency and the pathogenicity of EIF4G1 in PD in diverse populations worldwide. So far, the evidence of its role remains inconclusive.
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